Taiwan
· Delayed Price · Currency is TWD Adimmune Statistics
Total Valuation
Adimmune has a market cap or net worth of TWD 11.25 billion. The enterprise value is 12.01 billion.
| Market Cap | 11.25B |
| Enterprise Value | 12.01B |
Important Dates
The next estimated earnings date is Monday, November 11, 2024.
| Earnings Date | Nov 11, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Adimmune has 421.51 million shares outstanding. The number of shares has decreased by -0.44% in one year.
| Shares Outstanding | 421.51M |
| Shares Change (YoY) | -0.44% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 1.02% |
| Owned by Institutions (%) | 3.94% |
| Float | 314.35M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6.79 |
| PB Ratio | 2.24 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -19.75 |
| EV / Sales | 7.25 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -45.91 |
Financial Position
The company has a current ratio of 2.64, with a Debt / Equity ratio of 48.90.
| Current Ratio | 2.64 |
| Quick Ratio | 1.78 |
| Debt / Equity | 48.90 |
| Debt / EBITDA | n/a |
| Debt / FCF | -10.08 |
| Interest Coverage | -16.66 |
Financial Efficiency
Return on equity (ROE) is -12.97% and return on invested capital (ROIC) is -5.00%.
| Return on Equity (ROE) | -12.97% |
| Return on Assets (ROA) | -4.69% |
| Return on Capital (ROIC) | -5.00% |
| Revenue Per Employee | 2.94M |
| Profits Per Employee | -1.08M |
| Employee Count | 564 |
| Asset Turnover | 0.18 |
| Inventory Turnover | 1.08 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -19.19% in the last 52 weeks. The beta is 0.46, so Adimmune's price volatility has been lower than the market average.
| Beta (5Y) | 0.46 |
| 52-Week Price Change | -19.19% |
| 50-Day Moving Average | 28.16 |
| 200-Day Moving Average | 29.19 |
| Relative Strength Index (RSI) | 32.58 |
| Average Volume (20 Days) | 759,118 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Adimmune had revenue of TWD 1.66 billion and -607.92 million in losses. Loss per share was -1.45.
| Revenue | 1.66B |
| Gross Profit | 460.89M |
| Operating Income | -672.08M |
| Pretax Income | -741.28M |
| Net Income | -607.92M |
| EBITDA | -481.34M |
| EBIT | -672.08M |
| Loss Per Share | -1.45 |
Balance Sheet
The company has 2.25 billion in cash and 2.64 billion in debt, giving a net cash position of -389.11 million or -0.92 per share.
| Cash & Cash Equivalents | 2.25B |
| Total Debt | 2.64B |
| Net Cash | -389.11M |
| Net Cash Per Share | -0.92 |
| Equity (Book Value) | 5.39B |
| Book Value Per Share | 11.92 |
| Working Capital | 2.43B |
Cash Flow
In the last 12 months, operating cash flow was -74.99 million and capital expenditures -186.57 million, giving a free cash flow of -261.56 million.
| Operating Cash Flow | -74.99M |
| Capital Expenditures | -186.57M |
| Free Cash Flow | -261.56M |
| FCF Per Share | -0.62 |
Margins
Gross margin is 27.82%, with operating and profit margins of -40.57% and -36.70%.
| Gross Margin | 27.82% |
| Operating Margin | -40.57% |
| Pretax Margin | -44.75% |
| Profit Margin | -36.70% |
| EBITDA Margin | -29.06% |
| EBIT Margin | -40.57% |
| FCF Margin | -15.79% |
Dividends & Yields
Adimmune does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.44% |
| Shareholder Yield | 0.44% |
| Earnings Yield | -5.43% |
| FCF Yield | -2.32% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |